Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: BD who wrote (811)	5/11/1998 8:18:00 PM
From: StockDoc	Read Replies (1) \| Respond to of 887

I don't know about the "well connected" consulting firm but I know something about FDA. In this case, I would not count on "connections". The guy who heads the division and that handles the "case" at the FDA (Temple) is famous for his consistent, impartial and scientific approach to NDAs. In fact, he's developing FDA's strict and pretty clear guidelines for NDA processes. I doubt that even the Pope could pressure him into anything (e.g., Depocyt approval) that does not meet the minimal requirements. Other drugs might better work out for them (under conditions mentioned before), if they can get money. I wish them well.